The report provides a detailed analysis essential for establishing a Lifitegrast production plant. It encompasses all critical aspects necessary for Lifitegrast production, including the cost of Lifitegrast production, Lifitegrast plant cost, Lifitegrast production costs, and the overall Lifitegrast production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Lifitegrast production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Lifitegrast is a prescription medication mainly used for the treatment of dry eye disease, which is also known as keratoconjunctivitis sicca. It is primarily used in eye-care products for managing dry eye disease, where it helps reduce irritation, redness, and discomfort.
It reduces dryness, irritation, and redness by blocking the interaction between certain immune cells that cause inflammation on the surface of the eye. It serves as an important active ingredient in prescription eye drops designed to improve tear quality and ease symptoms linked to dryness, burning, and visual fatigue. It is generally used for providing relief to patients who do not respond well to standard lubricating drops. Moreover, it is also studied in research environments to better understand inflammatory responses in the eye and to explore whether similar mechanisms may be helpful in treating other ocular conditions.
The market for Lifitegrast is mainly driven by its use as a component in the treatment and management of dry eye disease, which contributes to its demand in the medical sector. Its application as an active ingredient in prescription eye drops to treat chronic dry eye is linked to immune system activity, which promotes its demand in the pharmaceutical industry. Its demand in the pharmaceutical research related to ocular inflammation and immune-mediated eye conditions further strengthens its market growth.
Its usage in managing inflammation associated with chronic dry eye and for advancements in targeted ophthalmic drug delivery systems also makes it a valuable product in the ophthalmic pharmaceutical sector. Factors such as the availability and cost of specialised chemical intermediates, compliance with stringent pharmaceutical production standards, and the need for cold-chain logistics to maintain product stability impact industrial Lifitegrast procurement. Ongoing research in ocular therapeutics, along with improved drug delivery technologies and strong distribution networks, also play a crucial role in shaping the global Lifitegrast market.
Raw Material for Lifitegrast Production
According to the Lifitegrast production plant project report, the major raw materials for Lifitegrast production include Amine (Boc-protected), Sodium Methanesulfinate, Potassium Carbonate, L-Proline, Benzyl Alcohol, Benzofuranyl Acid, and Saponification Reagents.
Production Process of Lifitegrast
The extensive Lifitegrast production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of Lifitegrast begins with Boc-protection of the starting amine, followed by a sulfonation reaction using sodium methanesulfinate with copper iodide, potassium carbonate, and L-proline to form a sulfonate intermediate. Then, this compound undergoes esterification with benzyl alcohol, and the Boc group is removed to form an aminoester as its HCl salt. This is coupled with a carboxylic acid to form an amide, which is further treated with hydrochloric acid in dioxane to remove the trityl group, which gives another HCl salt. Then, this intermediate is reacted with benzofuranyl acid to produce the benzyl ester of Lifitegrast. Finally, the resulting compound is subjected to saponification, which leads to the formation of Lifitegrast in its active form, as the desired compound.
Lifitegrast is a pharmaceutical solid that exists as a white to off-white powder with no characteristic odour. The molecular formula of the compound is C29H24Cl2N2O7S, and its molar mass is about 615.48 g/mol. Its density is around 1.48 g/cm3, and it is soluble in water. It has a high decomposition-related melting point above 163 degree Celsius and its boiling point is around 811.9 degree Celsius. It is also slightly soluble in methanol and DMSO. It is used as an active ingredient in ophthalmic solutions to treat dry eye disease by modulating integrin interactions. It is recommended to follow appropriate protective measures when handling the pure chemical because, like many bioactive compounds, it can cause irritation and other adverse effects if not handled carefully.